Souhaitez-vous accéder aux communiqués récents ?
Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.
-
YARDLEY, Pa., Nov. 27, 2017 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today reported...
-
YARDLEY, Pa., Nov. 20, 2017 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ENT and allergy specialists, today announced that the Company will...
-
YARDLEY, Pa., Nov. 17, 2017 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ENT and allergy specialists, today announced that Chief Executive...
-
YARDLEY, Pa., Nov. 08, 2017 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ENT and allergy specialists, today announced that Chief Executive...
-
YARDLEY, Pa., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ENT and allergy specialists, today announced the addition of five key...
-
YARDLEY, Pa., Oct. 17, 2017 (GLOBE NEWSWIRE) -- OptiNose, Inc. (NASDAQ:OPTN), a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by...
-
YARDLEY, Pa., Oct. 12, 2017 (GLOBE NEWSWIRE) -- OptiNose, Inc. (Optinose), a specialty pharmaceutical company focused on the development and commercialization of products for patients treated by...